This is with reference to the proposed acquisition of biosimilars assets of Viatris Inc., by Biocon Biologics Limited (BBL), subsidiary of Biocon Limited and in continuation to our letter dated November 17, 2022, please be informed that BBL has allotted equity shares to Biocon Limited for an amount of Rs. 2,205.63 crores(~US$ 270 Million) on November 23, 2022.